Peri‐arterial pathways for clearance of α‐Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy

Accumulation of amyloid beta (Aβ), α‐synuclein (αSyn), and tau in dementias indicates their age‐related failure of elimination from the brain. Aβ is eliminated along basement membranes in walls of cerebral arterioles and leptomeningeal arteries (intramural peri‐arterial drainage [IPAD]); IPAD is impaired with age. We test the hypothesis that αSyn and tau are also eliminated from the normal brain along IPAD pathways.

[1]  J. Kordower,et al.  Immunotherapy in Parkinson’s disease: Current status and future directions , 2019, Neurobiology of Disease.

[2]  L. Buée,et al.  From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy , 2019, Acta Neuropathologica.

[3]  J. Attems,et al.  Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions , 2019, Journal of neurochemistry.

[4]  D. Aarsland,et al.  The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology , 2019, European journal of neurology.

[5]  J. Wardlaw,et al.  Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial , 2019, EClinicalMedicine.

[6]  G. Johnson,et al.  It’s all about tau , 2019, Progress in Neurobiology.

[7]  L. Buée,et al.  A walk through tau therapeutic strategies , 2019, Acta Neuropathologica Communications.

[8]  R. Carare,et al.  Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain , 2019, Front. Aging Neurosci..

[9]  Alan J. Thomas,et al.  Dementia with Lewy bodies: an update and outlook , 2019, Molecular Neurodegeneration.

[10]  F. N. Emamzadeh,et al.  Cell Responses to Extracellular α-Synuclein , 2019, Molecules.

[11]  Roxana O. Carare,et al.  Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways , 2018, Acta Neuropathologica.

[12]  U. Sengupta,et al.  Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy , 2018, Molecular Neurodegeneration.

[13]  E. Masliah,et al.  Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy , 2017, Neurobiology of Disease.

[14]  U. Sengupta,et al.  Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies , 2017, Aging and disease.

[15]  J. Attems.  Alzheimer's disease pathology in synucleinopathies , 2017, The Lancet Neurology.

[16]  H. Fukuyama,et al.  A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol , 2016, Alzheimer's & dementia.

[17]  Ho Chul Kang,et al.  Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 , 2016, Science.

[18]  R. Carare,et al.  Vascular basement membranes as pathways for the passage of fluid into and out of the brain , 2016, Acta Neuropathologica.

[19]  Jacqueline Burré.  The Synaptic Function of α-Synuclein , 2015, Journal of Parkinson's disease.

[20]  D. Werring,et al.  White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid , 2015, Brain pathology.

[21]  Maiken Nedergaard,et al.  Impairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury , 2014, The Journal of Neuroscience.

[22]  K. Luk,et al.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite–like aggregates , 2014, Nature Protocols.

[23]  R. Carare,et al.  Failure of Perivascular Drainage of β‐amyloid in Cerebral Amyloid Angiopathy , 2014, Brain pathology.

[24]  R. Carare,et al.  Afferent and efferent immunological pathways of the brain. Anatomy, Function and Failure , 2014, Brain, Behavior, and Immunity.

[25]  V. Perry,et al.  Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer’s disease , 2013, Acta neuropathologica communications.

[26]  G. Landreth,et al.  Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[27]  H. Feldman,et al.  Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia , 2013, Alzheimer's Research & Therapy.

[28]  G. Johnson,et al.  Tau Clearance Mechanisms and Their Possible Role in the Pathogenesis of Alzheimer Disease , 2013, Front. Neurol..

[29]  R. Carare,et al.  Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid‐β from the mouse brain , 2013, Aging cell.

[30]  C. Zurzolo,et al.  Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* , 2012, The Journal of Biological Chemistry.

[31]  V. Perry,et al.  Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction , 2012, Acta Neuropathologica.

[32]  D. Holtzman,et al.  The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain , 2012, Brain Research.

[33]  D. Holtzman,et al.  In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice , 2011, The Journal of Neuroscience.

[34]  Evangelia Emmanouilidou,et al.  Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma , 2011, PloS one.

[35]  P. Brundin,et al.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.

[36]  Reinhard Schliebs,et al.  Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy , 2011, Acta Neuropathologica.

[37]  J. McLaurin,et al.  Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathy , 2009, Proceedings of the National Academy of Sciences.

[38]  R O Weller,et al.  Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. , 2008, Brain : a journal of neurology.

[39]  Tianhong Pan,et al.  The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. , 2008, Brain : a journal of neurology.

[40]  R O Weller,et al.  Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology , 2008, Neuropathology and applied neurobiology.

[41]  V. Perry,et al.  Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain , 2005, Glia.

[42]  S. D. Preston,et al.  Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.

[43]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[44]  M. Yamada,et al.  Cerebral amyloid angiopathy. , 2012, Progress in molecular biology and translational science.

[45]  R O Weller,et al.  Pathways of Fluid Drainage from the Brain ‐ Morphological Aspects and Immunological Significance in Rat and Man , 1992, Brain pathology.

[46]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[47]  E. Masliah,et al.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders , 2015, Neurotherapeutics.

[48]  C. Nicholson,et al.  Clearance systems in the brain-implications for Alzheimer disease. , 2015, Nature reviews. Neurology.